# US 2012/0252001 A1 · Method of Blood Pooling and Storage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252001 A1
- Document ID: US20120252001A1
- Status: Published application
- Kind: A1
- Application number: 13/483,379
- Filed: 2012-05-30
- Published: 2012-10-04
- Earliest claimed: 2010-11-29
- Assignees: New York Blood Center, Inc.
- Inventors: Beth Shaz; Christopher D. Hillyer
- Web page: https://patentgrep.com/patent/US20120252001A1

## CPC

- C12N 5/0641: {Erythrocytes}
- A01K 5/0114: {Pet food dispensers; Pet food trays (time-controlled A01K5/0291)}
- A01K 5/02: Automatic devices {(automatic identification devices for stock A01K11/006)}
- A01K 5/0291: {with timing mechanisms, e.g. pet feeders}
- A01N 1/10: Preservation of living parts
- A01N 1/122: Preservation or perfusion media
- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 35/18: Erythrocytes (haemoglobin A61K38/42)
- A61K 35/19: Platelets; Megacaryocytes
- A61M 1/0272: {Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging}
- A61M 1/342: {Adding solutions to the blood, e.g. substitution solutions (for preventing coagulation A61M1/3672)}
- A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)}
- C12N 5/0644: {Platelets; Megakaryocytes}
- A61M 2202/0429: Red blood cells; Erythrocytes
- A61M 2202/20: Pathogenic agents
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The disclosure provides methods of making a red blood cell, plasma, and platelet products having a uniform dose and volume. The method comprises pooling a plurality of blood units, leukoreducing the blood and inactivating any pathogen contained therein. Plasma, RBCs, and platelets are then divided into uniform dose and volume units which have an extended shelf life.

## Claims

### Claim 1

A method for preparing uniform dose blood components from a plurality of whole blood units of the same blood group and type comprising:
a) leukoreducing a plurality of individual whole blood units to form leukoreduced blood components, wherein the leukoreduced blood components comprises RBCs, platelets, and plasma;
b) pooling the leukoreduced blood components from the plurality of blood units;
c) treating the blood component to inactivate one or more pathogens;
d) separating an RBC component, a platelet component, and a plasma component from the blood component;
e) adding a storage solution to the RBC component and dividing the RBC into uniform volume and dose units;
f) adding a storage solution to the platelet component and dividing the platelets into uniform volume and dose units; and
g) dividing the plasma component into uniform volume and dose units.

### Claim 2 (depends on 1)

The method of claim 1, wherein the storage solution comprises at least one material selected from the group consisting of adenine, glucose, phosphate, mannitol, guanosine, and a combination thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the treating step inactivates one or more pathogens without damaging the structure or function of the cell component.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more pathogens are selected from the group consisting of viruses, bacteria, fungi, prions, parasites, and combinations thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more pathogens are inactivated by at least one method selected from the group consisting of irradiation, solvent and detergent, magnetophoresis, immunomagnetic bead technology, filtration, and a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1, wherein each unit of the RBC component contains about 1×1012 to about 5×1012 RBCs/unit.

### Claim 7 (depends on 1)

The method of claim 1, wherein each unit of the RBC component contains about 20-80 g of hemoglobin.

### Claim 8 (depends on 1)

The method of claim 1, wherein each unit of the platelet component contains about 2-6×1011 platelets/unit.

### Claim 9 (depends on 1)

The method of claim 1, further comprising the step of filtering out poorly-deformable RBCs from an RBC or blood component.

### Claim 10

A method for preparing a uniform dose blood components from a plurality of whole blood units of the same blood group and type comprising:
a) separating a cellular component and a plasma component from the plurality of whole blood units, wherein the cellular component comprises RBCs, platelets, and white blood cells;
b) pooling the cellular component from the plurality of blood units and pooling the plasma component from the plurality of blood units;
c) treating the pooled plasma component with a solvent/detergent to inactivate pathogens and dividing the pooled plasma into uniform volume and dose units;
d) leukoreducing the pooled cellular component;
e) treating the leukoreduced cellular component to inactivate one or more pathogens;
f) separating the leukoreduced cellular component into an RBC component and a platelet component;
g) adding a storage solution to the RBC component and dividing the RBCs into uniform volume and uniform dose aliquots; and
h) adding a storage solution to the platelet component and dividing the platelets into uniform volume and uniform dose aliquots.

### Claim 11 (depends on 10)

The method of claim 10, wherein the storage solution comprises at least one material selected from the group consisting of adenine, glucose, phosphate, mannitol, guanosine, and a combination thereof.

### Claim 12 (depends on 10)

The method of claim 10, wherein the treating step inactivates one or more pathogens without damaging the structure or function of the cell component.

### Claim 13 (depends on 10)

The method of claim 10, wherein the one or more pathogens are selected from the group consisting of viruses, bacteria, fungi, prions, parasites, and combinations thereof.

### Claim 14 (depends on 10)

The method of claim 10, wherein the one or more pathogens are inactivated by at least one method selected from the group consisting of irradiation, solvent and detergent, magnetophoresis, immunomagnetic bead technology, filtration and a combination thereof.

### Claim 15 (depends on 10)

The method of claim 10, wherein each unit of the RBC component contains about 1×1012 to about 5×1012 RBCs/unit.

### Claim 16 (depends on 10)

The method of claim 10, wherein each unit of the RBC component contains about 20-80 g of hemoglobin.

### Claim 17 (depends on 10)

The method of claim 10, wherein each unit of the platelet component contains about 2-6×1011 platelets/unit.

### Claim 18 (depends on 10)

The method of claim 10, further comprising the step of filtering out poorly-deformable RBCs from the RBC or cellular component.

### Claim 19

A method for preparing uniform dose blood components from a plurality of whole blood units of the same blood group and type comprising:
a) leukoreducing a plurality of individual whole blood units to form leukoreduced blood components, wherein the leukoreduced blood components comprises RBCs, platelets, and plasma;
b) pooling the leukoreduced blood components from the plurality of blood units;
c) treating the blood component to inactivate one or more pathogens;
d) separating at least one of an RBC component, a platelet component, and a plasma component from the leukoreduced blood component; and
e) dividing the at least one of RBCs, platelets, and plasma into uniform volume and dose units.

### Claim 20 (depends on 19)

The method of claim 19, wherein the blood component is separated into at least two, or all three, of RBCs, platelets, and plasma from the leukoreduced blood component.

### Claim 21

A method for preparing a uniform dose blood components from a plurality of whole blood units of the same blood group and type comprising:
a) separating a cellular component and a plasma component from the plurality of whole blood units, wherein the cellular component comprises RBCs, platelets, and white blood cells;
b) pooling the cellular component from the plurality of blood units and pooling the plasma component from the plurality of blood units;
c) treating the pooled plasma component with a solvent/detergent to inactivate pathogens and dividing the pooled plasma into uniform volume and dose units;
d) leukoreducing the pooled cellular component;
e) treating the leukoreduced cellular component to inactivate one or more pathogens;
e) separating the leukoreduced cellular component into at least one of an RBC component and a platelet component; and
f) dividing the at least one of an RBC component and a platelet component into uniform volume and dose units.
